It is generally accepted that oxidative stress plays a key role in the pathogenesis of diabetes mellitus (DM) and its vascular complications (6, 7, 12, 14, 18, 49) . Markers of oxidative stress were shown to be elevated in a diabetic animal model and in patients with DM (40, 43) . In addition to the increased production of reactive oxygen species (ROS) in DM, the antioxidant capacity is decreased, and oxidative stress is associated with obesity and insulin resistance (4, 15, 21, 26, 47) . Therefore, treatment with antioxidants or overexpression of antioxidant enzymes can, at least partially, prevent oxidative stressinduced insulin resistance (20, 24, 26, 36) .
Peroxisome proliferator-activated receptor ␥ (PPAR␥) is a member of the superfamily of nuclear receptors. PPAR␥ heterodimerizes with retinoid X receptor ␣ (RXR␣) and binds to a specific DNA sequence called peroxisome proliferator response element (PPRE). PPAR␥ is activated when specific ligands bind to the ligand-binding domain. Thiazolidinediones (TZDs), such as troglitazone, rosiglitazone, and pioglitazone, are well-known PPAR␥ ligands and have been used for the treatment of diabetes. PPAR␥ is most abundantly expressed in adipose tissues and plays a key role in adipocyte differentiation (42, 46) . Since the expression level of PPAR␥ in muscle is low, the effect of PPAR␥ ligands on insulin sensitivity in muscle has been explained by the connection between adipose tissue and muscle: activation of PPAR␥ in adipose tissue decreases the plasma fatty acid levels and modulates the expression of adipokines that contribute to improving insulin resistance in muscle (13) . However, the direct role of PPAR␥ on insulin sensitivity in muscle has been demonstrated in a muscle-specific PPAR␥-knockout mouse model (23) . Several reports have demonstrated that TZDs, being used to improve insulin sensitivity, also have antioxidant effects; however, little is known regarding the mechanism involved in the antioxidant effect of TZDs (9, 26, 32) .
Glutathione peroxidases (GPxs) are members of the family of antioxidant enzymes that scavenge hydrogen peroxide in the presence of reduced glutathione, and seven isoforms having different substrate specificities and tissue distribution have been identified (5, 11, 44) . GPx is a selenium-dependent enzyme that contains a selenium atom incorporated within the selenocysteine residue (30) . GPx3, also called plasma GPx, is an extracellular enzyme that catalyzes organic hydroperoxides and lipid hydroperoxides as well as hydrogen peroxide (35, 51) . GPx3 is highly expressed in the kidney; however, GPx3 mRNA is also found in the lung, heart, liver, eyes, and white adipose tissue (8, 37, 39, 52) .
In this study, in order to examine the antioxidant effects of TZDs, human muscle cells were exposed to H 2 O 2 that was being generated continuously from glucose oxidase and glucose in the medium. Destruction of insulin signaling by treatment with H 2 O 2 or glucose oxidase in vascular smooth muscle cells and adipocytes has been reported (16, 45) . Here, we show that high levels of H 2 O 2 destroy the insulin signaling pathway, and TZDs prevent H 2 O 2 -induced insulin resistance in human skeletal muscle cells. This study also provides evidence that PPAR␥ directly regulates the expression of a gene coding for performed using 5% skim milk, and primary antibody in 0.1% Tween 20-Trisbuffered saline was then added. Hybridized primary antibodies were detected using a horseradish peroxidase-conjugated species-specific immunoglobulin G antibody. The bands were visualized by enhanced chemiluminescence (Pierce, Rockford, IL).
Northern blot analysis. Total RNAs were isolated by using the TRIzol reagent kit (Invitrogen) or RNeasy minikit (Qiagen, Hilden, Germany) according to the manufacturer's instructions. The RNAs (20 g) were separated by electrophoresis and transferred onto a Nytran membrane (NY 13-N; Schleicher & Schuell, Stanford, ME). The membranes were prehybridized in QuickHyb hybridization solution (Stratagene), hybridized with [␣-
32 P]dATP-labeled cDNA fragments of GPx3 or glyceraldehyde-3-phosphate dehydrogenase (GAPDH), and exposed to X-ray films. To prepare RNA from tissues, fresh frozen tissues were ground in a mortar chilled with liquid nitrogen, the powdered tissues were added to TRIzol (Invitrogen), and total RNA was prepared.
Treatment with glucose oxidase and measurement of H 2 O 2 . Human muscle cells were differentiated, and the medium was then changed to phenol red-free minimum essential medium (Invitrogen) supplemented with 2% FBS. Cells were treated with PPAR␥ agonists, adenovirus, or short interfering RNA (siRNA) for 48 h, and then glucose oxidase was added to the medium. The amount of H 2 O 2 in the medium was measured using a method described previously (36) . Absorbance was measured at 491 nm (VersaMax; Molecular Devices, Sunnyvale, CA) using t-butyl hydroperoxide as the standard. N-Acetylcysteine (NAC; 10 mM; Sigma-Aldrich) and recombinant catalase (1,600 mU/ml; Sigma-Aldrich) treatment was performed prior to the addition of glucose oxidase.
Determination of intracellular ROS. Human muscle cells were treated with glucose oxidase and were washed three times with PBS. The cells were incubated with 10 g/ml 2Ј,7Ј-dichlorohydrofluorescein diacetate (DCF-DA; Invitrogen) in PBS for 5 min and were washed. Fluorescence was detected by excitation at 485 nm and emission at 535 nm using a Victor 3 instrument (Perkin-Elmer, Boston, MA).
Microarray analysis. Human skeletal muscle cells were differentiated and treated with troglitazone (10 M) or dimethyl sulfoxide (DMSO) (control) for 48 h. Total RNAs were isolated by using the RNeasy midiprep kit (Qiagen, Hilden, Germany) and subjected to microarray analysis (Human Oligo 10K chip; Macrogen, Seoul, South Korea).
Transient-transfection and reporter assays. COS-7 cells were transiently transfected with luciferase reporter vectors containing different lengths of the human GPx3 promoter (0.3 g), pcDNA-PPAR␥ (0.05 g), pFLAG-RXR␣ (0.05 g), and pCMV-␤Gal (0.05 g) using Lipofectamine Plus reagent (Invitrogen). COS-7 cells were transfected with 0.15 g of the reporter vectors [pGL2P, pGL2P (Ϫ2186) PPRE, or pGL2P (Ϫ2186) PPREmt], pcDNA-PPAR␥ (0.03 g), pFLAG-RXR␣ (0.03 g), and pCMV-␤Gal (0.05 g). Troglitazone (10 M) and 9-cis-retinoic acid (1 M) were added 3 h after transfection, and the cells were incubated for 40 h. The cells were harvested for the analysis of luciferase activity (Promega), and the relative transfection efficiency was determined by measuring ␤-galactosidase activity.
Electrophoretic mobility shift assay (EMSA). Oligonucleotides for hGPX3 (Ϫ2186) PPRE (Ϫ2195/Ϫ2169 bp) (TAGACCACCAGGGCTGGGATTAAG GTG, upper strand) and the (Ϫ2186) PPRE mutant (TAGACCACCAGGGC TGcctaatAGGTG, upper strand) were used as a probe or competitor. The sequence of consensus PPRE competitor was CAGGGGACCAGGACAAAG GTCACGTTGCGGA. The probes were labeled with [␣-32 P]dATP using Klenow polymerase (Ambion, Austin, TX), and the labeled probe (25,000 cpm) was incubated with the nuclear extracts of the human skeletal muscle cells treated with troglitazone or rosiglitazone for 48 h in 10 mM HEPES (pH 7.9) containing 50 mM KCl, 0.1 mM EDTA, 0.25 mM dithiothreitol (DTT), 0.1 mg/ml poly(dIdC), 0.01% Nonidet P-40, and 10% glycerol at room temperature for 10 min. Competitors were added at 50-or 100-fold molar excesses to the labeled probe. The DNA-protein complexes were separated on 5% polyacrylamide gels and were detected by autoradiography.
Chromatin immunoprecipitation (ChIP). The differentiated human skeletal muscle cells were treated with rosiglitazone for 48 h. The cells were cross-linked in 1% formaldehyde at 37°C for 10 min and were resuspended in buffer 1 (100 mM Tris-HCl, pH 9.4; 10 mM DTT; protease inhibitors). The nuclei were isolated in buffer 2 (10 mM Tris-HCl, pH 8.0; 0.25% X-100; 0.5% NP-40; 10 mM EDTA; 0.5 mM EGTA; 1 mM DTT; protease inhibitors) by centrifugation. Nuclear extracts were prepared in buffer 3 (10 mM Tris-HCl, pH 8.0; 1 mM EDTA; 0.5 mM EGTA; 1 mM DTT; protease inhibitors) and sonicated. The nuclear extracts (500 l) were then incubated overnight with anti-PPAR␥ antibody (3 g), salmon sperm DNA (2 g), and protein G-Sepharose (20 l) at 4°C in radioimmunoprecipitation assay buffer. After being washed several times, the immunoprecipitates were eluted using an elution buffer (1% SDS and 0.1 M VOL. 29, 2009 GPx3 MEDIATES THE ANTIOXIDANT EFFECTS OF PPAR␥ 21 NaHCO 3 ). To reverse the cross-linking, the immunoprecipitates were incubated in 200 mM NaCl, and the DNA was purified by phenol-chloroform and ethanol precipitation. The following primers were used for PCR: 5Ј-GCCCATGGGAA GTAGGATGT-3Ј and 5Ј-TGGGATTATAGGCACCACCA-3Ј (Ϫ7234 PPRE candidate), 5Ј-TGTGACCAGCCCCTAACAAA-3Ј and 5Ј-GGAGGACTCAC AGAACTCAGCA-3Ј (Ϫ5442 PPRE candidate), 5Ј-CAGCACAGATCAGTTT GTACTAGCC-3Ј and 5Ј-GAAAACCTTAGCGGCTTTCCT-3Ј (Ϫ4651 PPRE candidate), and 5Ј-AGCAATCCAGGGGTAGCATC-3Ј and 5Ј-CCCTGCTCT CAAAGGTGTTTC-3Ј (Ϫ2186 PPRE candidate). Transfection of siRNA. The siRNAs of hGPx3 and hPPAR␥ were purchased from Dharmacon, Lafayette, CO. The siRNA of the negative control (NS) was purchased from Bioneer, Seoul, South Korea. The siRNA (On-Targetplus Smart pool or NS; 100 nM) was incubated with Lipofectamine 2000 (Invitrogen) in 100 l serum-free medium for 15 min. The siRNA-Lipofectamine 2000 complex was then added to the cells in 400 l of serum-containing medium and maintained for 3 days.
GPx3 ELISA. The gene encoding human GPx3 whose internal selenocysteine had been mutated to cysteine was amplified by PCR. For producing the recombinant GPx3 protein in human embryonic kidney (HEK) 293 cells, the DNA sequence encoding hGPx3 (Gln21 to Lys226) was tagged with FLAG at the C terminus, and its secretion was facilitated using PAI-1 leader peptide. Polyclonal antibody was prepared from rabbits according to the general protocols. Immunoglobulin fractions were prepared from serum. A sandwich enzyme-linked immunosorbent assay (ELISA) format that used FLAG-tagged GPx3 was designed. The extracellular GPx3 protein levels in the medium were measured by using ELISA kits. The plasma GPx3 concentration was also measured in 49 subjects with type 2 DM and in age-and sex-matched subjects with normal glucose tolerance (NGT; n ϭ 57) and impaired glucose tolerance (IGT; n ϭ 48) by using ELISA kits. The status of NGT, IGT, and DM was determined on performing the 75-g oral glucose tolerance test according to the diagnostic criteria of the American Diabetes Association (1).
Statistical analysis. Statistical analysis was performed using GraphPad InStat (version 3.05; GraphPad Software Inc.). The differences between the means were assessed by Student's t test or one-way analysis of variance. The data have been expressed as the means Ϯ standard errors of the means. A P value of less than 0.05 was considered to denote a statistically significant difference.
RESULTS

Treatment with
TZDs overcomes the effect of ROS on insulin signaling and glucose transport in human skeletal muscle cells. To investigate whether TZD modulates the effect of ROS on the insulin signaling pathway in skeletal muscle cells, we prepared human skeletal muscle cells and incubated them with glucose oxidase, which continuously produces H 2 O 2 using glucose as a substrate. When the cells were incubated with glucose oxidase (100 mU/ml) for 3.5 h in the absence of troglitazone, insulin-stimulated tyrosine phosphorylation of IRS-1 and phosphorylation at serine 473 of Akt/PKB were completely inhibited (Fig. 1A) . This was similar to the result found by other researchers in experiments involving 3T3-L1 adipocytes (45) . Pretreatment with troglitazone, a member of the TZDs, for 48 h completely restored insulin-induced activation of IRS-1 and Akt in the presence of glucose oxidase (Fig. 1A ). Next, we tested the effect of troglitazone on the glucose uptake in human skeletal muscle cells. When the cells were incubated with a high level of H 2 O 2 generated by glucose oxidase, glucose uptake was significantly decreased in both the basal and insulin-stimulated states (Fig. 1B) . Pretreatment with troglitazone, however, increased the glucose uptake by three-to fourfold both in the absence and in the presence of insulin and completely ameliorated the effect of H 2 O 2 .
PPAR␥ is involved in the antioxidant effect of TZDs. To determine whether the protective effect of TZDs against ROS was PPAR␥ dependent, a PPAR␥ antagonist, GW9662, was added to the medium. The antioxidant effect of troglitazone almost disappeared in the presence of GW9662 ( Fig. 2A) . A similar effect was observed when PPAR␥ expression was knocked down by transfection with PPAR␥ siRNAs: the antioxidant effect of rosiglitazone was completely abolished by knockdown of PPAR␥ (Fig. 2B ). These results suggested that the antioxidant effect of TZDs was PPAR␥ dependent. When the cells were treated with troglitazone for 3 h instead of 48 h, insulin-induced phosphorylation of IRS-1 and Akt was not observed in the presence of glucose oxidase (Fig. 2C) . In addition, the antioxidant effect of troglitazone disappeared when the culture medium was replaced with fresh medium before treatment with glucose oxidase (Fig. 2D ). To summarize these results, an extracellular protein was involved in the antioxidant effect of TZDs, and the expression of this protein was induced by PPAR␥ activation.
TZDs decrease extracellular H 2 O 2 levels. Since the data in Fig. 2 showed that an extracellular protein was involved in the (A) Human skeletal muscle cells were prepared and differentiated as described in Materials and Methods. The cells were treated with glucose oxidase (100 mU/ml) for 3 h and then with insulin (100 nM) for 30 min. For troglitazone treatment, the cells were pretreated with troglitazone for 48 h and then with glucose oxidase and insulin. The cells were harvested, and 20 g of proteins was subjected to SDSpolyacrylamide gel electrophoresis and Western blot analysis. (B) Glucose uptake was measured as described in Materials and Methods. The cells were treated with glucose oxidase (100 mU/ml) for 3 h and then incubated with or without insulin (100 nM) for 30 min. For troglitazone treatment, the cells were pretreated with troglitazone for 48 h and then with glucose oxidase and insulin. The glucose uptake of untreated cells was set as 100, and the other values were expressed relative to it. The bar graph represents the mean Ϯ standard error of four independent experiments; * , P Ͻ 0.01 versus the basal value of control cells not treated with troglitazone; ** , P Ͻ 0.01 versus the corresponding value of control cells not treated with troglitazone, †, P Ͻ 0.01 versus the corresponding value of cells treated with glucose oxidase but not with TZDs. (Fig. 3A) . However, when the cells were incubated with troglitazone for less than 6 h, the H 2 O 2 level did not decrease, and the longer the duration of troglitazone treatment, the lower the H 2 O 2 levels that were elicited (Fig. 3B) . Similar results were obtained when rosiglitazone was used (data not shown). Furthermore, each of the three TZDs, namely, troglitazone, rosiglitazone, and pioglitazone, reduced the H 2 O 2 levels in the medium (Fig. 3C ). To test whether gene expression was involved in this effect, cycloheximide, a protein synthesis inhibitor (10 g/ml), was added to the cells simultaneously with TZDs. Treatment with cycloheximide completely inhibited the effect of troglitazone and rosiglitazone (Fig. 3D ). This result showed that the antioxidant effect of TZDs is completely dependent on the synthesis of a protein.
TZDs decrease intracellular ROS levels. Next, we directly examined the level of intracellular ROS in the presence of glucose oxidase and TZDs. Incubation with glucose oxidase significantly increased the intracellular ROS concentration, which was detected by DCF fluorescence, and treatment with TZDs decreased the intracellular ROS levels to almost the basal levels (Fig. 3E) . The effects of the increase in the intracellular ROS levels by glucose oxidase treatment were investigated in greater detail: activation of ROS-responsive Ser/Thr kinases, such as JNK, p38, and Erk1/2, was examined. Phosphorylation of JNK, p38, and Erk1/2 was increased in line with the increase in the intracellular ROS levels by glucose oxidase, and TZDs suppressed the activation of these kinases (Fig. 3F) .
Similar results were obtained from IKK phosphorylation and phosphorylation at Ser307 of IRS-1 (Fig. 3F) . These results clearly showed that the extracellular H 2 O 2 produced by glucose oxidase entered into the cells and increased the intracellular ROS levels and that TZDs decreased the intracellular ROS levels by downregulation of the extracellular H 2 O 2 .
Effect of PPAR␥ activation on the expression of GPx3. To determine the gene whose expression is induced by PPAR␥ activation and which is involved in the antioxidant effect of TZDs, we used microarray analysis to examine the expression patterns of many genes in human skeletal muscle cells treated with troglitazone. Several genes, such as CD 36, adipose differentiation-related protein, and apolipoprotein E, which are known to be targets of PPAR␥, were induced by PPAR␥ activation (see Fig. S1 in the supplemental material). Interestingly, the expression of GPx3 was dramatically increased by PPAR␥ activation; however, the expression of a number of genes encoding other antioxidant enzymes was hardly changed (see Fig. S1 in the supplemental material). To confirm the findings of the microarray analysis, the mRNA level of GPx3 was determined by Northern blot analysis. The GPx3 mRNA level was dramatically increased by troglitazone and was further increased by PPAR␥ overexpression in the cultured human skeletal muscle cells (Fig. 4A) . In contrast, the GPx1 mRNA level was not increased by troglitazone, suggesting that this effect is specific to the GPx3 gene and cannot be generalized to other members of the GPx family. While rosiglitazone, pioglitazone, and troglitazone increased the mRNA level of GPx3, wy14643-a PPAR␣ ligand-did not increase the GPx3 mRNA level (Fig. 4B) . Expression of the GPx3 gene was gradually increased by rosiglitazone up to 48 h (Fig. 4C) . Similar results were obtained with troglitazone and pioglitazone (data Since PPAR␥ and RXR␣ bind to a target DNA sequence (PPRE) as a heterodimer, we tested the effect of an RXR␣ agonist, 9-cis-retinoic acid, on the expression of GPx3. A synergistic increase in GPx3 mRNA expression was detected after simultaneous treatment with troglitazone and 9-cis-retinoic acid (Fig. 4D) . When PPAR␥ was activated by TZDs in mouse C2C12 myotubes, GPx3 expression was also increased (data not shown), indicating that the regulation of the GPx3 gene by PPAR␥ is conserved between species. In addition to the determination of GPx3 at the mRNA level, the increase in GPx3 by PPAR␥ activation was also determined at the protein level by ELISA, and the result showed that extracellular GPx3 protein level was increased by troglitazone (Fig. 4E) .
Identification of a PPRE in the human GPx3 promoter. To investigate whether PPAR␥ directly affects GPx3 promoter activity, DNA fragments representing the human GPx3 promoter were linked to the luciferase reporter gene. Activation of PPAR␥ and RXR␣ increased the promoter activity of hGPx3 (Ϫ2294) Luc by approximately 3.5-fold in COS7 cells (Fig. 5A) . In contrast, PPAR␥ activation had little effect on the activity of a smaller construct, hGPx3 (Ϫ809) Luc. A DNA sequence similar to the consensus PPRE was found at Ϫ2186/ Ϫ2174 bp of the human GPx3 gene. We also performed ChIP: four regions in the GPx3 promoter presumed to contain PPRE candidates (Ϫ7234, Ϫ5442, Ϫ4651, and Ϫ2186 PPRE candidates) were tested. Among these candidates, only the PPRE candidate at Ϫ2186 in the hGPx3 promoter could be immunoprecipitated with the anti-PPAR␥ antibody (Fig. 5B) . In our study, the binding activity of PPAR␥ was not changed by rosiglitazone, and similar phenomena have been reported by other researchers (10, 19) . EMSA with in vitro-translated PPAR␥ and RXR␣ showed that they specifically bound to hGPx3 (Ϫ2186) PPRE (data not shown). In addition, EMSA using nuclear extracts of human skeletal muscle cells and competitors also proved that this sequence is a specific PPRE (Fig.  5C ). An oligomer containing a mutated sequence in hGPx3 (Ϫ2186) PPRE did not compete with the probe (lanes 5 and 6), and an oligomer representing the consensus PPRE competed well with the hGPx3 PPRE probe (lanes 7 and 8). To further investigate the function of this sequence as a PPRE, a DNA fragment representing two copies of this sequence was inserted into the region upstream of the SV promoter in the pGL2-pro vector. PPAR␥ activation increased the promoter activity of GPx3 (Ϫ2186) PPRE Luc (Fig. 5D) . In contrast, when the PPRE sequence was mutated, the effect of PPAR␥ activation on the transcriptional activity was totally abolished. These results suggested that PPAR␥ directly regulates the expression of GPx3 by binding to the PPRE.
Effect of overexpression of GPx3 on ROS levels. We next tested whether overexpression of GPx3 directly affects the extracellular H 2 O 2 concentration and the insulin signaling pathway in skeletal muscle cells. Overexpression of GPx3 by infection with Ad-GPx3 was confirmed on its mRNA (Fig. 6A) . While GPx3 expression was increased, the extracellular H 2 O 2 concentration was decreased in the presence of glucose oxidase (Fig. 6B) . In addition, activation of ROS-responsive factors, such as JNK, p38, and Erk1/2, by glucose oxidase was inhibited by overexpression of GPx3 (Fig. 6C) , thereby proving that the increase in the intracellular ROS levels in the presence of glucose oxidase was protected by overexpression of GPx3. Consistent with this result, the insulin signaling pathway was restored almost completely by the overexpression of GPx3 in the presence of glucose oxidase (Fig. 6D) .
Role of GPx3 in the antioxidant effect of TZDs. To determine the contribution of GPx3 to the antioxidant effect of TZDs, we knocked down GPx3 gene expression by transfection with GPx3 siRNAs and examined the antioxidant effect of TZDs. Administration of PPAR␥ siRNA or GPx3 siRNA significantly reduced the level of PPAR␥ or GPx3 mRNA, respectively (Fig. 7A) . In addition, induction of GPx3 expression by TZDs was also repressed by PPAR␥ siRNA, clearly suggesting that GPx3 expression is regulated by PPAR␥. The extracellular H 2 O 2 concentration in the presence of TZDs was significantly increased by the suppression of PPAR␥ or GPx3 expression (Fig. 7B) . Consistent with this finding, the antioxidant effect of rosiglitazone observed on the ROS-responsive factors, including JNK, p38, and Erk1/2, was abolished when GPx3 expression was suppressed by specific siRNAs (Fig. 7C) . In addition, rosiglitazone could not restore the insulin signaling pathway impaired by glucose oxidase in the presence of GPx3 siRNA (Fig. 7D) . A similar effect was observed in the glucose uptake levels: the antioxidant effect of troglitazone was inhibited by knockdown of GPx3 (Fig. 7E) . Based on these results, we conclude that GPx3 is a major protein involved in the antioxidative effect of TZDs.
Expression of GPx3 in diabetic patients and animal models. Next, we examined the relationship between GPx3 expression and diabetes. Plasma GPx3 levels in patients with type 2 DM were significantly lower than those in subjects with NGT or IGT (Fig.  8A) . The plasma GPx3 protein concentration in db/db mice was also lower than that in normal mice (data not shown). In addition, the GPx3 mRNA level was decreased in the skeletal muscles of db/db mice (Fig. 8B ). Further investigation with the high-fat diet model showed that mice fed with the high-fat diet had lower GPx3 expression levels than those fed with the standard chow, and rosiglitazone treatment increased the GPx3 expression levels in the high-fat diet-fed mice (Fig. 8C) . These results strongly suggested the existence of a relationship between the GPx3 expression level and diabetes.
DISCUSSION
Oxidative stress has been proposed to play an important role in the pathogenesis of insulin resistance, diabetes, and diabetic vascular complications. ROS activates serine/threonine kinase cascades, such as JNK and mitogen-activated protein kinase cascades, leading to serine phosphorylation of the insulin receptor or IRS-1 and results in impaired insulin signaling (4, 31, 36) . In this study, we induced insulin resistance in human skeletal muscle cells by adding glucose oxidase to the culture media. To confirm that the impairment in insulin signaling shown in these experiments was induced by H 2 O 2 produced by glucose oxidase, NAC, a well-known antioxidant, was added to the medium. Treatment with NAC led to complete recovery of insulin-induced phosphorylation of IRS-1 and Akt in the presence of glucose oxidase (see Fig. S2 in the supplemental material), suggesting that the H 2 O 2 produced by glucose oxidase FIG. 5 . Identification of a PPRE in the hGPx3 gene. (A) COS-7 cells were transfected with the indicated vectors containing the hGPx3 promoter (hGPx3 (Ϫ2294) Luc or hGPx3 (Ϫ809) Luc), the expression vectors of PPAR␥, RXR␣, and ␤-galactosidase. Rosiglitazone (Rosi) (10 M) and 9-cis-retinoic acid (RA) (1 M) were added for 48 h. ␤-Galactosidase activity was used as an internal control to monitor the transfection efficiency. The luciferase activity of hGPx3 (Ϫ2294) Luc in the absence of PPAR␥/RXR␣ expression and agonists was set as 1, and other activities were expressed relative to it. The bar graph represents the mean Ϯ standard error of six independent experiments. * , P Ͻ 0.01 versus the activity of hGPx3 (Ϫ2294) Luc without PPAR␥/RXR␣ and their agonists. (B) ChIP was performed on human skeletal muscle cells treated or not treated with rosiglitazone. Immunoprecipitation was performed using control immunoglobulin G or anti-PPAR␥ antibody (␣-PPAR␥). PCR was performed using the primers described in Materials and Methods, and 10% of the cell lysates used for immunoprecipitation was used as the input. Similar results were obtained from three independent experiments. (C) EMSA was performed using an oligomer representing hGPx3 PPRE at Ϫ2186 as a probe and nuclear extracts of human skeletal muscle cells treated with rosiglitazone. For competition assays, unlabeled oligomers representing the hGPx3 (Ϫ2186) PPRE (self) (lanes 3 and 4), PPRE mutant (mt) (lanes 5 and 6), or a consensus PPRE (PPRE) (lanes 7 and 8) were used at a 50-or 100-fold molar excess. Lane 1 shows only the probe, and lane 2 shows the control without the competitor. (D) COS-7 cells were transiently transfected with pGL2P, pGL2P (Ϫ2186) PPRE, or pGL2P (Ϫ2186) PPREmt, expression vectors of PPAR␥ and RXR␣, and pCMV-␤-galactosidase. Luciferase activity was normalized by ␤-galactosidase activity, the value of pGL2P Luc without any treatment was set as 1, and other activities were expressed in relation to it. The bar graph represents the mean Ϯ standard error of four independent experiments. * , interferes with the insulin signaling pathway. The H 2 O 2 concentration in the medium reached 1 mM after incubation with glucose oxidase (100 mU/ml) for 3.5 h. This concentration of H 2 O 2 is similar to that used in other reports in which insulin resistance was induced in in vitro cell culture systems of HEK 293 and 3T3-L1 adipocytes (21, 45) . This concentration may not be physiological; however, the intracellular H 2 O 2 concentration would be much lower than the extracellular H 2 O 2 concentration because H 2 O 2 gradients are established across the plasma membrane despite H 2 O 2 being small enough to diffuse directly into the cells (2) . We directly detected the increase in intracellular ROS levels and the activation of ROS-responsive Ser/Thr kinases, such as JNK and mitogen-activated protein kinase, by glucose oxidase (Fig. 3E and F) . Insulin-induced phosphorylation of IRS-1 and Akt was completely inhibited by H 2 O 2 generated by glucose oxidase, and glucose uptake was also impaired in our cell culture system (Fig. 1) . We confirmed the antioxidant effect of TZDs in skeletal muscle cells by showing that TZDs restored the insulin signaling pathway and insulin-induced glucose uptake, which were impaired by H 2 O 2 .
The results shown in Fig. 2 and 3 indicate that an extracellular protein whose expression was induced by TZDs mediated the antioxidant effect of TZDs by reducing the extracellular ROS levels. Therefore, we need to confirm whether addition of an antioxidant protein to the medium can modulate intracellular ROS levels and the insulin signaling pathway by reducing extracellular ROS levels. Recombinant catalase, a well-known antioxidant enzyme, was added to the medium, and its protective effect against glucose oxidase treatment was examined. In the presence of catalase, the glucose oxidase-induced increase in the extracellular and intracellular ROS levels was significantly suppressed (see Fig. S3A and B in the supplemental material), and insulin signaling occurred normally (see Fig.  S3C in the supplemental material), suggesting that induction of an extracellular antioxidant protein may modulate the intracellular oxidative status.
Among the antioxidant enzyme genes, a functional PPRE in the rat catalase promoter has been reported (17) . However, the microarray analysis results of our study (see Fig. S1 in the supplemental material) showed that GPx3 expression in skeletal muscle cells was significantly increased by TZD treatment, while the expression of the other antioxidant enzyme-encoding genes such as the other GPx family members, Mn superoxide dismutases and catalase, were hardly affected. Therefore, we could hypothesize that in skeletal muscle, the PPAR␥-dependent-antioxidant effect of TZDs is exclusively mediated by GPx3. Finally, we observed that GPx3 knockdown by siRNA treatment almost abolished the antioxidant effects of TZDs in the skeletal muscle cells, which strongly supported our hypothesis. We, however, could not exclude the possibility that another mechanism(s) is also involved in the antioxidant effect of TZDs. PPAR␥ activation has been reported to negatively regulate the expression of NADPH oxidase, resulting in decreased ROS production in endothelial cells (27) . Troglitazone has been reported to have a direct antioxidant-scavenging activity on free radicals, unlike other TZDs (9) . Eventually, however, we believe that the increased expression of GPx3 is the major mechanism for the antioxidant effect of TZDs in skeletal muscle cells because PPAR␥ and a secreted protein are important for the antioxidant effect of TZDs (Fig. 2) , and GPx3 siRNA significantly inhibits the antioxidant effect of TZDs (Fig. 7) . The mitochondrion is a major organelle concerned with the production of ROS in cells, and chronic treatment of glucose and free fatty acids increases the ROS levels in muscle and other tissues (14) . In addition, inflammatory cytokines such as tumor necrosis factor alpha (TNF-␣) also increase ROS levels and the increased ROS may contribute to the induction of insulin resistance, although other mechanisms are also involved in the induction of insulin resistance by these factors (34) . To test whether TZD-mediated GPx3 expression can affect insulin resistance induced by TNF-␣, human muscle cells were treated with TNF-␣ (see Fig. S4 in the supplemental material). As expected, TNF-␣ treatment impaired the insulin signaling pathway, and rosiglitazone partially alleviated insulin resistance. Interestingly, GPx3 knockdown partially inhibited the effect of rosiglitazone, suggesting an important role of GPx3 in the protective function of TZDs against insulin resistance.
In this study, we showed that the plasma GPx3 level is decreased in newly diagnosed, drug-naive diabetic patients compared to subjects with IGT or NGT. Plasma ROS levels have been reported to be significantly higher in diabetic animals (28); therefore, reduction of plasma GPx3 may be an important reason for the elevation of plasma ROS levels. Several reports illustrate the relationship between GPx3 levels and the pathogenesis of various diseases. Renal GPx3 expression is reduced in long-term diabetic NOD mice but is increased in new-onset diabetic NOD mice (50) . Decreased GPx3 levels are associated with arterial thrombosis in ischemic heart disease patients (41) and familial childhood stroke (29) . A promoter polymorphism in the GPx3 gene is associated with reduced gene expression and arterial ischemic stroke (48) . Plasma GPx3 deficiency impairs normal inhibition of platelet activation by NO, thereby resulting in hyperreactive platelet aggregation (29) . These observations suggest that a low level of GPx3 is associated with cardiovascular diseases and diabetes. We also observed that GPx3 expression in the muscle tissues of db/db mice and high-fat diet-fed mice was lower than that of normal mice. In contrast, little difference was observed between the renal tissues-where GPx3 is most abundantly expressed-obtained from these two groups of mice (data not shown). We are unaware regarding the contribution of each The cells were treated with siRNAs, rosiglitazone, and glucose oxidase sequentially as described above and then with insulin for 30 min. Western blot analysis was then performed. (E) Glucose uptake was measured using siRNA-treated cells. The value from the cells that had been transfected with NS siRNA and not treated with either glucose oxidase or troglitazone was set as 100, and the other values were shown in relation to it. The bar graph shows the mean Ϯ standard error of five independent experiments. ‫,ء‬ P Ͻ 0.05 versus troglitazone-and glucose oxidase-treated cells of siNS. type of tissue expressing GPx3 to the determination of the plasma GPx3 level; however, it is possible that a reduction in GPx3 expression in the muscle tissue in diabetic subjects can at least influence the oxidative stress around the muscle. The mechanism behind the downregulation of GPx3 in DM is currently unknown. Since GPx3 expression was observed to have decreased in the muscle tissue of type 2 diabetic patients and of db/db and DIO mice, it may be due to common factors in these insulin-resistant states such as hyperinsulinemia, hyperglycemia, or low-grade inflammation. Recently, we and our coworkers found that in adipose tissue, GPx3 expression is reduced by inflammation or hypoxia (33) . Little is known regarding the regulation of GPx3 expression, and therefore, further intensive study is required to elucidate the mechanism by which the GPx3 level is downregulated in DM. In conclusion, the results of this study suggest that GPx3 plays an important role against oxidative stress and may be a therapeutic target for insulin resistance and DM.
